Published in Neuropsychopharmacology on October 01, 2003
Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Adv Nutr (2011) 1.45
Cognitive and physiological effects of an "energy drink": an evaluation of the whole drink and of glucose, caffeine and herbal flavouring fractions. Psychopharmacology (Berl) (2004) 1.45
Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl) (2005) 1.44
Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. Psychopharmacology (Berl) (2010) 0.95
The use of herbal medicine in Alzheimer's disease-a systematic review. Evid Based Complement Alternat Med (2006) 0.92
Anxiolytic and antidepressant-like effects of Melissa officinalis (lemon balm) extract in rats: Influence of administration and gender. Indian J Pharmacol (2012) 0.91
Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab (2010) 0.87
Effects of IAA, IBA, NAA, and GA3 on rooting and morphological features of Melissa officinalis L. stem cuttings. ScientificWorldJournal (2013) 0.87
An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl) (2008) 0.84
Traditional Chinese medicine: a promising candidate for the treatment of Alzheimer's disease. Transl Neurodegener (2013) 0.84
Melissa officinalis extract inhibits laser-induced choroidal neovascularization in a rat model. PLoS One (2014) 0.78
Behavioral, neurochemical and neuroendocrine effects of abnormal savda munziq in the chronic stress mice. Evid Based Complement Alternat Med (2012) 0.77
Anti-stress effects of lemon balm-containing foods. Nutrients (2014) 0.77
Adverse Psychiatric Effects Associated with Herbal Weight-Loss Products. Biomed Res Int (2015) 0.77
Combined Administration of Melissa officinalis and Boswellia serrata Extracts in an Animal Model of Memory. Iran J Psychiatry Behav Sci (2016) 0.75
Does melissa officinalis cause withdrawal or dependence? Med Arch (2015) 0.75
Effects of Ncl. Basalis Meynert volume on the Trail-Making-Test are restricted to the left hemisphere. Brain Behav (2015) 0.75
Influence of the Melissa officinalis Leaf Extract on Long-Term Memory in Scopolamine Animal Model with Assessment of Mechanism of Action. Evid Based Complement Alternat Med (2016) 0.75
Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS One (2015) 0.75
The Effects of Methanolic Extract of Melissa officinalis on Experimental Gastric Ulcers in Rats. Iran Red Crescent Med J (2016) 0.75
Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Clinical Evidence and Possible Mechanisms. Evid Based Complement Alternat Med (2017) 0.75
The effects of powdered fertilized eggs on depression. J Med Food (2011) 0.75
Interaction of Plant Extracts with Central Nervous System Receptors. Medicines (Basel) (2017) 0.75
Avicenna's pharmacological approach to memory enhancement. Neurol Sci (2017) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J (1978) 3.59
Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry (1985) 2.47
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics (1997) 2.28
Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci (1990) 2.24
Autism as a disorder of neural information processing: directions for research and targets for therapy. Mol Psychiatry (2004) 2.19
Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology (1999) 2.00
Necropsy evidence of central cholinergic deficits in senile dementia. Lancet (1977) 1.97
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology (2000) 1.85
Serum 25-hydroxyvitamin D and cognitive decline in the very old: the Newcastle 85+ Study. Eur J Neurol (2014) 1.85
A rapid method for preparing synaptosomes: comparison, with alternative procedures. Brain Res (1981) 1.85
Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci (1977) 1.83
Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol (1978) 1.82
Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci (1983) 1.51
Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med (1992) 1.49
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain (1999) 1.48
Cognitive properties of sedation agents: comparison of the effects of nitrous oxide and midazolam on memory and mood. Br Dent J (1999) 1.45
Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology (2004) 1.38
Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet (1986) 1.35
The cholinergic hypothesis--ten years on. Br Med Bull (1986) 1.31
Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav (2002) 1.28
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol (1994) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol (1998) 1.17
Clinically and neuropathologically distinct form of dementia in the elderly. Lancet (1989) 1.16
Two time windows of anisomycin-induced amnesia for passive avoidance training in the day-old chick. Neurobiol Learn Mem (1995) 1.15
Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett (1982) 1.14
Glucose administration, heart rate and cognitive performance: effects of increasing mental effort. Psychopharmacology (Berl) (2000) 1.13
Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) (1981) 1.11
Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res (2004) 1.08
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol (2002) 1.07
The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003). Psychopharmacology (Berl) (2003) 1.07
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic 'compartment' of pyruvate dehydrogenase. Neurosci Lett (1980) 1.06
Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci (1981) 1.05
Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study. J Psychopharmacol (2005) 1.05
Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form. Neurosci Lett (1983) 1.05
The influence of agonal status on some neurochemical activities of postmortem human brain tissue. Neurosci Lett (1982) 1.04
Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav (2003) 1.03
Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience (1998) 1.02
The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl) (2000) 1.02
Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology (2004) 1.02
Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum. Neuroscience (2002) 1.01
Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease. Life Sci (1980) 1.00
Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem (1986) 1.00
Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience (2000) 0.98
Selective changes in nicotinic acetylcholine receptor subtypes related to tobacco smoking: an immunohistochemical study. Neuropathol Appl Neurobiol (2004) 0.98
Improved cognitive performance and mental fatigue following a multi-vitamin and mineral supplement with added guaraná (Paullinia cupana). Appetite (2007) 0.97
Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem (1999) 0.97
The cholinergic system in old age and Alzheimer's disease. Age Ageing (1980) 0.97
Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. J Neurol Neurosurg Psychiatry (1987) 0.96
Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry (1983) 0.96
Comparison of the binding of nicotinic agonists to receptors from human and rat cerebral cortex and from chick brain (alpha 4 beta 2) transfected into mouse fibroblasts with ion channel activity. Brain Res (1994) 0.96
A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment. Curr Med Res Opin (1991) 0.96
Validity of a cognitive computerized assessment system in brain-injured patients. Brain Inj (1998) 0.95
Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav (2003) 0.94
Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav (2002) 0.94
Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Brain Res Dev Brain Res (1997) 0.93
Plasma and erythrocyte acetylcholinesterase in senile dementia of Alzheimer type. Lancet (1982) 0.93
Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. Brain (1991) 0.93
Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas. J Neurochem (1982) 0.92
Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology (2007) 0.92
The substantia innominata and adjacent regions in the human brain: histochemical and biochemical observations. J Anat (1984) 0.92
Cortical cholinergic dysfunction after human head injury. J Neurotrauma (1998) 0.92
Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord (2001) 0.91
Cholinergic systems in progressive supranuclear palsy. Brain (2005) 0.91
Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. Pharmacol Biochem Behav (2003) 0.91
5-HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Disord (1987) 0.91
Oxygen administration selectively enhances cognitive performance in healthy young adults: a placebo-controlled double-blind crossover study. Psychopharmacology (Berl) (1998) 0.91
[3H]MK-801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging. Brain Res (1992) 0.91
Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin Chim Acta (1996) 0.90
Water ingestion improves subjective alertness, but has no effect on cognitive performance in dehydrated healthy young volunteers. Appetite (2001) 0.90
The effects of multivitamin supplementation on mood and general well-being in healthy young adults. A laboratory and at-home mobile phone assessment. Appetite (2013) 0.90
Self-rated everyday and prospective memory abilities of cigarette smokers and non-smokers: a web-based study. Drug Alcohol Depend (2004) 0.90
Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology (2008) 0.90
Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiol Aging (1981) 0.89
Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type. J Neurol Sci (1984) 0.89
Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J Neurochem (1998) 0.89
Blood acetyl- and butyrylcholinesterases in senile dementia of Alzheimer type. J Neurol Sci (1985) 0.89
Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia (1994) 0.89
Differential nicotinic acetylcholine receptor subunit expression in the human hippocampus. J Chem Neuroanat (2003) 0.89
Improved cognitive performance in human volunteers following administration of guarana (Paullinia cupana) extract: comparison and interaction with Panax ginseng. Pharmacol Biochem Behav (2004) 0.89
Cholinergic receptors in cognitive disorders. Can J Neurol Sci (1986) 0.89
Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. Neurobiol Learn Mem (2008) 0.88
Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav (2005) 0.88
Histochemical observations on cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. Age Ageing (1980) 0.88
Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci (1983) 0.88
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry (2000) 0.88